| Metric | Value (₹ Cr) | vs Q3 FY25 |
|---|---|---|
| Revenue | 328.36 | 17.5% |
| Total Income | 335.82 | 16.4% |
| Expenditure | 296.52 | 10.1% |
| PBT | 39.30 | 69.2% |
| Net Profit | 27.81 | 72.6% |
| OPM | 15.55% | 10.92pp |
| NPM | 8.28% | 16.99pp |
| EPS | 21.67 | 72.6% |
Neuland Laboratories Q4FY25 Total Income at Rs.335.8 crore; EBITDA at Rs.58.2 crore
15 May 2025 · 15 May 2025, 04:28 pm
Key Highlights
- 1
Neuland Laboratories Q4FY25 Total Income at Rs.335.8 crore
- 2
EBITDA at Rs.58.2 crore
- 3
Marginal decrease in topline in FY25 as compared to FY24
- 4
Commitment to making investments for medium and long term growth
- 5
CMS revenues of Rs. 637 crores driven by molecules in the commercial segment
- 6
Peptide investment plan on track
- 7
Molecules in the portfolio currently at the take off stage
- 8
Expected growth trajectory to resume in FY26
- 9
FY25 Total Income: Rs. 1,497.3 crore, down 4.7% from FY24
- 10
FY25 EBITDA: Rs. 342.8 crore, down 27.7% from FY24
- 11
FY25 PAT: Rs. 259.4 crore, down 13.4% from FY24
Informational and educational content only. Not investment advice.